Products
Research Areas
COVID-19
Resources
Login
Quick Order
Cart
Login
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.


Fields marked with a * are required.

Login
Quick Order
Contact Us

Locations


Orders Processing,
Shipping & Receiving,
Warehouse

2 Shaker Rd Suites
B001/B101
Shirley, MA 01464


Production Lab

Floor 6, Suite 620
20700 44th Avenue W
Lynnwood, WA 98036

Telephone Numbers



Tel: +1 (206) 374-1102
Fax: +1 (206) 577-4565

Contact Us



Additional Contact Details

Login
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.


Fields marked with a * are required.

Login
Quick Order
Catalog Number Size Price
LS-G3949-10 10 µg $351 
FLT3LG / Flt3 Ligand Protein - Influence of FLT3L treatment on lymphocyte subpopulations. Method: C57BL/6 mice were injected intraperitoneally with 10 ug daily or were left untreated. (A) Percentages of indicated splenic subpopulations in FLT3L KO, WT control or WT-treated mice. (B) Absolute cell numbers of indicated splenic subpopulations in FLT3L KO, WT control, or WT-treated mice.

Human FLT3LG / Flt3 Ligand Protein (Recombinant Human IgG1 Fc) - LS-G3949

Human FLT3LG / Flt3 Ligand Protein (Recombinant Human IgG1 Fc) - LS-G3949

Description:
FLT3LG / Flt3 Ligand Protein LS-G3949 is a Recombinant Human FLT3LG / Flt3 Ligand produced in CHO Cells aa1-185 with Human IgG1 Fc tag(s). It is low in endotoxin; Less than 0.1 EU/µg protein (determined by LAL method). For Research Use Only
Price
Catalog Number
$351
LS-G3949-10
Toll Free North America
206-374-1102
For Research Use Only

Overview

Description:
FLT3LG / Flt3 Ligand Protein LS-G3949 is a Recombinant Human FLT3LG / Flt3 Ligand produced in CHO Cells aa1-185 with Human IgG1 Fc tag(s). It is low in endotoxin; Less than 0.1 EU/µg protein (determined by LAL method). For Research Use Only

Specifications

Type
Recombinant Protein
Target
FLT3LG / Flt3 Ligand
Synonyms
FLT3LG | FL | Flt3 ligand | FLT3L | SL cytokine
Species
Human
Modifications
Unmodified
Conjugations
Unconjugated
Tag
Human IgG1 Fc
Region
aa1-185
Expression System
CHO Cells
Source Species
Hamster-Chinese
Purification
Greater than 95% by SDS-PAGE
Bio-Activity
In vitro and in vivo generation of conventional and plasmacytoid dendritic cells (DC). FLT3L increases in vivo both NK and DC cells numbers in the spleen when mice are injected intraperitoneally with 2 or 10 µg, daily for 10 days (slightly higher effect at 10 µg).
Endotoxin
Less than 0.1 EU/µg protein (determined by LAL method).
Presentation
Sterile Solution PBS
Reconstitution
Reconstitute with 100ul sterile distilled water.
Storage
Stable for at least 6 months after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C.
Restrictions
For research use only. Intended for use by laboratory professionals.
Guarantee
This protein carries the LSBio 100% Guarantee.
LSBio Guarantee
About FLT3LG / Flt3 Ligand
P49771 NM_001459 NP_001450.2

Publications (0)

Customer Reviews (0)

Images

Functional Assay

FLT3LG / Flt3 Ligand Protein - Influence of FLT3L treatment on lymphocyte subpopulations. Method: C57BL/6 mice were injected intraperitoneally with 10 ug daily or were left untreated. (A) Percentages of indicated splenic subpopulations in FLT3L KO, WT control or WT-treated mice. (B) Absolute cell numbers of indicated splenic subpopulations in FLT3L KO, WT control, or WT-treated mice.
Influence of FLT3L treatment on lymphocyte subpopulations. Method: C57BL/6 mice were injected intraperitoneally with 10 ug daily or were left untreated. (A) Percentages of indicated splenic subpopulations in FLT3L KO, WT control or WT-treated mice. (B) Absolute cell numbers of indicated splenic subpopulations in FLT3L KO, WT control, or WT-treated mice.

Functional Assay

FLT3LG / Flt3 Ligand Protein - Influence of FLT3L treatment on lymphocyte subpopulations. Method: C57BL/6 mice were injected intraperitoneally with 10 ug daily or were left untreated. (A) Percentages of indicated splenic subpopulations in FLT3L KO, WT control or WT-treated mice. (B) Absolute cell numbers of indicated splenic subpopulations in FLT3L KO, WT control, or WT-treated mice.
Influence of FLT3L treatment on lymphocyte subpopulations. Method: C57BL/6 mice were injected intraperitoneally with 10 ug daily or were left untreated. (A) Percentages of indicated splenic subpopulations in FLT3L KO, WT control or WT-treated mice. (B) Absolute cell numbers of indicated splenic subpopulations in FLT3L KO, WT control, or WT-treated mice.

Functional Assay

FLT3LG / Flt3 Ligand Protein - Influence of FLT3L treatment on lymphocyte subpopulations. Method: C57BL/6 mice were injected intraperitoneally with 10 ug daily or were left untreated. (A) Percentages of indicated splenic subpopulations in FLT3L KO, WT control or WT-treated mice. (B) Absolute cell numbers of indicated splenic subpopulations in FLT3L KO, WT control, or WT-treated mice.
Influence of FLT3L treatment on lymphocyte subpopulations. Method: C57BL/6 mice were injected intraperitoneally with 10 ug daily or were left untreated. (A) Percentages of indicated splenic subpopulations in FLT3L KO, WT control or WT-treated mice. (B) Absolute cell numbers of indicated splenic subpopulations in FLT3L KO, WT control, or WT-treated mice.

Functional Assay

FLT3LG / Flt3 Ligand Protein - Influence of FLT3L treatment on lymphocyte subpopulations. Method: C57BL/6 mice were injected intraperitoneally with 10 ug daily or were left untreated. (A) Percentages of indicated splenic subpopulations in FLT3L KO, WT control or WT-treated mice. (B) Absolute cell numbers of indicated splenic subpopulations in FLT3L KO, WT control, or WT-treated mice.
Influence of FLT3L treatment on lymphocyte subpopulations. Method: C57BL/6 mice were injected intraperitoneally with 10 ug daily or were left untreated. (A) Percentages of indicated splenic subpopulations in FLT3L KO, WT control or WT-treated mice. (B) Absolute cell numbers of indicated splenic subpopulations in FLT3L KO, WT control, or WT-treated mice.

Request SDS/MSDS

To request an SDS/MSDS form for this product, please contact our Technical Support department at:

Technical.Support@LSBio.com

Requested From: United States
Date Requested: 4/24/2024